Results 121 to 130 of about 3,283 (198)

Cross-Sectional Survey of Real-World Physician Prescribing Practices for Anti-VEGF Agents in the Treatment of Neovascular Age-Related Macular Degeneration and Associated Patient Burden in the United States

Clinical Ophthalmology
Shilpa Gulati,1,2 Emily Coak,3 Daniel Mascia,3 Katherine Li,3 Stella Ko,4 Nicole Gidaya Bonine4 1New England Retina Consultants, Springfield, MA, USA; 2Massachusetts Chan Medical School, University of Massachusetts, Worcester, MA, USA; 3Adelphi Real ...
Gulati S, Coak E, Mascia D, Li K, Ko S, Bonine NG   +5 more
doaj  

Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature

Eye and Vision
Background This article describes a rare occurrence of bilateral retinal occlusive vasculitis secondary to intravitreal faricimab injection. Case presentation A 72-year-old female with age-related macular degeneration presented with bilateral retinal ...
Yong Min Lee, Rajya Gurung, Jagjit Singh Gilhotra, Sumu Simon, Sudha Cugati   +4 more
doaj   +1 more source

Bilateral Neovasküler Yaşa Bağlı Makula Dejenerasyonunda Aflibersept ve Faricimab ile Uygulanan İntravitreal Tedavilerin Anatomik ve Fonksiyonel Sonuçlarının Karşılaştırılması

GİRİŞ VE AMAÇ:Bu olguda, bilateral neovasküler yaşa bağlı makula dejenerasyonu (n-YBMD) tanılı 65 yaşındaki kadın hastada, bir göze uygulananaflibersept (Eylea), diğer göze başlanan faricimab (Vabysmo) enjeksiyonlarının anatomik ve görsel yanıtlar ...
Koçak, Nilüfer, Devebacak, Ali, Karacabağ, Kağan   +2 more
core   +1 more source

Faricimab Reverts VEGF-A165-Induced Impairment of the Barrier Formed by Retinal Endothelial Cells

VEGF-A165-induced persistent dysfunction of the barrier formed by immortalized bovine retinal endothelial cells (iBREC) is only transiently reverted by inhibition of VEGF-A-driven signaling.
Isabell Fuezy, Heidrun L. Deissler, Lyubomyr Lytvynchuk, Dominik M. Jung   +3 more
core   +1 more source

From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME. [PDF]

J Clin Med
Ruiz-Moreno JM, Bernal-Morales C, Esteban-Floría O, Rodríguez-de-la-Rúa E, Remolí-Sargues L, Borras-Blasco J, Gómez-Benlloch A, Cilveti E, Valsero-Franco S, Arriola-Naharro C, García-Lunar P, Kaminski-Santamaría S, Muñoz-Molina B, García-Layana A.   +13 more
europepmc   +1 more source

Case Report: Faricimab in the treatment of subretinal fluid secondary to choroidal osteoma without definite evidence of CNV. [PDF]

Front Med (Lausanne)
Ren R, He Y, Shang Y, Hu Y, Liu C, Yang X.   +5 more
europepmc   +1 more source

Choroidal Vascular Remodeling After Loading Injections of Faricimab in Diabetic Macular Edema. [PDF]

Transl Vis Sci Technol
Kim J, Han YE, Kim YJ, Lee J.
europepmc   +1 more source

Faricimab in the Treatment of Retinal Disease: A Narrative Review. [PDF]

Cureus
Zeaiter M, Jaber H, Gharbi K, Fernandes SMB, Mchaik J, Ahmed M, Hassan A, Hammoud AA.   +7 more
europepmc   +1 more source

Faricimab 6 mg Versus Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Protocol-Standardised In Silico Study. [PDF]

Pharmaceuticals (Basel)
Panos GD.
europepmc   +1 more source

Real-world comparative effectiveness of faricimab versus aflibercept 2 mg in treatment-naïve exudative neovascular AMD patients treated with a treat-and-extend regimen. [PDF]

Eye (Lond)
Zhuang X, Ulla L, Foti C, Cariola R, Neri G, Olivieri C, Parisi G, Petrillo F, Marolo P, Reibaldi M, Borrelli E.   +10 more
europepmc   +1 more source